soul trial oral semaglutide cardiovascular outcomes 2025 results news today in High- Risk Type 2 Diabetes: Benefit Confirmed in the SOUL Trial Shows Oral Semaglutide – Semaglutide 2.4 mg delivered a – oral semaglutide cardiovascular benefit soul

TFAP2A could bind to the promoter region of the de-ubiquitination enzyme OTUB1, thus enhancing OTUB1 expression

An arginine substitution at position 34 removes an immunogenic risk present in native GLP-1

See the full release here

Participants also experienced improved mood and daytime performance, suggesting DSIP may help with both sleep quality and overall alertness

The development of novel dual- or triple-receptor agonists that bind to the receptors not only for GLP-1 but also to the receptors for glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon is intended to address different metabolic pathways for carbohydrate, lipid, and protein metabolism simultaneously

( A ) The intrinsic potency of TZP ( n = 23) in the presence of casein (CAS) is equivalent to GIP(1-42) ( n = 49)